BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 24581097)

  • 1. Alcohol septal ablation for hypertrophic obstructive cardiomyopathy - 8 years follow up.
    Sathyamurthy I; Nayak R; Oomman A; Subramanyan K; Kalarical MS; Mao R; Ramachandran P
    Indian Heart J; 2014; 66(1):57-63. PubMed ID: 24581097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: a systematic review of published studies.
    Alam M; Dokainish H; Lakkis N
    J Interv Cardiol; 2006 Aug; 19(4):319-27. PubMed ID: 16881978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survival after transcoronary ablation of septal hypertrophy in hypertrophic obstructive cardiomyopathy (TASH): a 10 year experience.
    Kuhn H; Lawrenz T; Lieder F; Leuner C; Strunk-Mueller C; Obergassel L; Bartelsmeier M; Stellbrink C
    Clin Res Cardiol; 2008 Apr; 97(4):234-43. PubMed ID: 18071624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel approach in the use of radiofrequency catheter ablation of septal hypertrophy in hypertrophic obstructive cardiomyopathy.
    Shelke AB; Menon R; Kapadiya A; Yalagudri S; Saggu D; Nair S; Narasimhan C
    Indian Heart J; 2016; 68(5):618-623. PubMed ID: 27773399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy: A 16-Year Australian Single Centre Experience.
    Nogic J; Koh Y; Bak M; Gooley RP; Meredith IT; McCormick LM
    Heart Lung Circ; 2018 Dec; 27(12):1446-1453. PubMed ID: 29129561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: Acute results and three-year noninvasive follow-up in 18 patients.
    Guo H; Wang J; Chen J; Shan J; Lee JD; Ueda T
    Can J Cardiol; 2004 Jun; 20(8):779-82. PubMed ID: 15229758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of surgical septal myectomy and alcohol septal ablation with cardiac magnetic resonance imaging in patients with hypertrophic obstructive cardiomyopathy.
    Valeti US; Nishimura RA; Holmes DR; Araoz PA; Glockner JF; Breen JF; Ommen SR; Gersh BJ; Tajik AJ; Rihal CS; Schaff HV; Maron BJ
    J Am Coll Cardiol; 2007 Jan; 49(3):350-7. PubMed ID: 17239717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Left ventricular longitudinal systolic function after alcohol septal ablation for hypertrophic obstructive cardiomyopathy: a long-term follow-up study focused on speckle tracking echocardiography.
    Sommer A; Poulsen SH; Mogensen J; Thuesen L; Egeblad H
    Eur J Echocardiogr; 2010 Dec; 11(10):883-8. PubMed ID: 20667848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk marker profiles in patients treated with percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy.
    Burghardt A; van Buuren F; Dimitriadis Z; Grübbel T; Seggewiss H; Scholtz S; Horstkotte D; Faber L
    Clin Res Cardiol; 2018 Jun; 107(6):479-486. PubMed ID: 29453593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: acute results and 3-month follow-up in 25 patients.
    Seggewiss H; Gleichmann U; Faber L; Fassbender D; Schmidt HK; Strick S
    J Am Coll Cardiol; 1998 Feb; 31(2):252-8. PubMed ID: 9462563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of coil embolization of the septal perforator for septal ablation in patients with hypertrophic obstructive cardiomyopathy.
    Guerrero I; Dhoble A; Fasulo M; Denktas AE; Sami S; Choi S; Balan P; Arain SA; Smalling RW
    Catheter Cardiovasc Interv; 2016 Nov; 88(6):971-977. PubMed ID: 27511120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Timing of invasive septal reduction therapies and outcome of patients with obstructive hypertrophic cardiomyopathy.
    Cavigli L; Fumagalli C; Maurizi N; Rossi A; Arretini A; Targetti M; Passantino S; Girolami F; Tomberli B; Baldini K; Tomberli A; Antoniucci D; Yacoub MH; Marchionni N; Stefano PL; Cecchi F; Olivotto I
    Int J Cardiol; 2018 Dec; 273():155-161. PubMed ID: 30213605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypertrophic obstructive cardiomyopathy: comparison of outcomes after myectomy or alcohol ablation adjusted by propensity score.
    Ralph-Edwards A; Woo A; McCrindle BW; Shapero JL; Schwartz L; Rakowski H; Wigle ED; Williams WG
    J Thorac Cardiovasc Surg; 2005 Feb; 129(2):351-8. PubMed ID: 15678046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Septal ethanol ablation for hypertrophic obstructive cardiomyopathy: early and intermediate results of a Canadian referral centre.
    Bhagwandeen R; Woo A; Ross J; Wigle ED; Rakowski H; Kwinter J; Eriksson MJ; Schwartz L
    Can J Cardiol; 2003 Jul; 19(8):912-7. PubMed ID: 12876612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypertrophic obstructive cardiomyopathy-alcohol septal ablation vs. myectomy: a meta-analysis.
    Alam M; Dokainish H; Lakkis NM
    Eur Heart J; 2009 May; 30(9):1080-7. PubMed ID: 19233857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute and long-term results after transcoronary ablation of septal hypertrophy (TASH). Catheter interventional treatment for hypertrophic obstructive cardiomyopathy.
    Gietzen FH; Leuner CJ; Raute-Kreinsen U; Dellmann A; Hegselmann J; Strunk-Mueller C; Kuhn HJ
    Eur Heart J; 1999 Sep; 20(18):1342-54. PubMed ID: 10462469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transcoronary ablation of septal hypertrophy (TASH): a new treatment option for hypertrophic obstructive cardiomyopathy.
    Kuhn H; Gietzen FH; Leuner C; Schäfers M; Schober O; Strunk-Müller C; Obergassel L; Freick M; Gockel B; Lieder F; Raute-Kreinsen U
    Z Kardiol; 2000; 89 Suppl 4():IV41-54. PubMed ID: 10810776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current effectiveness and risks of isolated septal myectomy for hypertrophic obstructive cardiomyopathy.
    Smedira NG; Lytle BW; Lever HM; Rajeswaran J; Krishnaswamy G; Kaple RK; Dolney DO; Blackstone EH
    Ann Thorac Surg; 2008 Jan; 85(1):127-33. PubMed ID: 18154797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term clinical follow-up of patients undergoing percutaneous alcohol septal reduction for symptomatic obstructive hypertrophic cardiomyopathy.
    Fortunato de Cano S; Nicolas Cano M; de Ribamar Costa J; Alves Pinheiro J; Bellio de Mattos Barretto R; Costa de Souza Le Bihan D; Abizaid A; Sousa A; Eduardo Sousa J
    Catheter Cardiovasc Interv; 2016 Nov; 88(6):953-960. PubMed ID: 27143093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Septal myotomy-myectomy and transcoronary septal alcohol ablation in hypertrophic obstructive cardiomyopathy. A comparison of clinical, haemodynamic and exercise outcomes.
    Firoozi S; Elliott PM; Sharma S; Murday A; Brecker SJ; Hamid MS; Sachdev B; Thaman R; McKenna WJ
    Eur Heart J; 2002 Oct; 23(20):1617-24. PubMed ID: 12323162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.